Precision oncology is the branch of precision medicine focused on providing a personalized, molecularly informed approach to cancer treatment. While this approach holds tremendous promise, the question still remains: Will precision oncology change how we treat cancer, and what should we be doing about it?
Many companies do currently offer tumor molecular profiling services in support of adopting a precision oncology-driven approach to treatment. However, these services all too often come with an exorbitantly high price tag, thereby limiting patients’ access to these potentially ground-breaking tools for treatment. In response to this finding, Strata Oncology (the precision medicine firm which recently closed a $26 million deal with Pfizer and Merck), has employed a largely unique cost-directing strategy in an attempt to change this reality.
Strata Oncology looks to change the precision oncology ecosystem, creating a “win-win” situation for all stakeholders. Their offering will maximize positive treatment outcomes and improve the standard of care for advanced stage cancer patients.